Trials / Recruiting
RecruitingNCT06508684
Current Status of BTKi Treatment for CLL/SLL in China
Current Status and Influencing Factors of Chinese Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Undergoing Treatment With Bruton's Tyrosine Kinase Inhibitors
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,000 (estimated)
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
BTKi has become the standard treatment regimen for CLL/SLL，there is a lack of large-scale real-world studies on the use status and related influencing factors of BTK inhibitors. Therefore, we plan to conduct this multicenter retrospective cross-sectional study to understand the current situation of BTK inhibitor treatment for CLL/SLL patients in China and the related influencing factors, and to explore more suitable treatment patterns based on this.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BTK inhibitor | BTKi can refer to Orelabrutinib, Ibrutinib, Zanubrutinib, and Acalabrutinib |
Timeline
- Start date
- 2024-07-13
- Primary completion
- 2025-02-12
- Completion
- 2025-07-12
- First posted
- 2024-07-18
- Last updated
- 2024-07-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06508684. Inclusion in this directory is not an endorsement.